We use cookies to display personalized content, analyze site traffic, provide recommendations, and ensure you have a great browsing experience. By continuing to use our site, you consent to our use of cookies. Privacy Policy.
Psilocybin, psilocin, MDMA, and other psychedelics are Schedule III controlled substances under Canada’s Controlled Drugs and Substances Act (CDSA). Legal possession, production, research, or distribution requires either a Dealer’s Licence or a Section 56 exemption from Health Canada. QSS works with pharmaceutical companies, research institutions, and clinical programs to navigate the full CDSA licensing process — from initial assessment and application preparation through facility inspection readiness and ongoing compliance.
Psilocybin and psilocin, the active compounds in psilocybin mushrooms, are listed under Schedule III of the CDSA. MDMA (3,4-methylenedioxymethamphetamine) is listed under Schedule I. Activities involving these substances, including possession, production, sale, import, export, and administration, are prohibited unless specifically authorized by Health Canada through a Dealer’s Licence or a Section 56 exemption.
Research interest in psychedelics has grown significantly in recent years, with clinical studies examining psilocybin and MDMA for conditions including treatment-resistant depression, anxiety, PTSD, and problematic substance use. Health Canada has a pathway for authorized research and therapeutic programs, but the licensing requirements are strict and the application process is detailed.
Understanding which authorization pathway applies to your specific activities, and preparing a complete, well-documented application, is the most important factor in how quickly your program can move forward.
Dealer's Licence
A Dealer’s Licence under the CDSA authorizes an organization to possess, produce, package, sell, import, export, distribute, and conduct laboratory analysis with controlled substances — the primary authorization for commercial and research organizations working with psychedelics at scale. Qualifying requires meeting Health Canada’s physical security standards, valid personnel security clearances, and quality systems in place before a licence is issued. Health Canada’s Office of Controlled Substances targets a 270-day review period from receipt of a complete application.
Section 56 Exemption
A Section 56 exemption under the CDSA allows specific individuals or organizations to work with controlled substances for defined purposes, including research, clinical trials, and therapeutic programs, without holding a full Dealer’s Licence. Exemptions are granted on a case-by-case basis and require an approved research or therapeutic protocol, ethics board approval, qualified personnel, and appropriate security and record-keeping measures. This is typically the pathway for clinical researchers, universities, and approved psychedelic-assisted therapy programs.
Not Sure Which Applies?
The right pathway depends on the substances involved, the scale and nature of your activities, and whether you are conducting research, running a therapeutic program, or operating commercially. We assess your situation and tell you exactly which authorization you need before any application work begins.
A CDSA Dealer’s Licence for psychedelics can authorize the following activities, depending on the scope of your application:
Health Canada requires the following as part of a complete Dealer’s Licence application for controlled substances:
Before any documentation is prepared, we assess your organization’s activities, substances, and goals to determine the correct authorization pathway. We confirm whether a Dealer’s Licence or Section 56 exemption applies, identify the specific activities your licence needs to cover, and give you a realistic picture of the timeline and process.
We prepare the complete Dealer’s Licence or Section 56 exemption application package on your behalf. This includes the application form, corporate documentation, QPIC and SPIC documentation packages, record-keeping system descriptions, and security documentation. We review every component for accuracy and completeness before filing with Health Canada’s Office of Controlled Substances.
Health Canada requires controlled substances facilities to meet specific physical security standards before a licence is issued. We conduct a pre-application site assessment against CDSA security requirements, identify gaps in your current setup, and support implementation of the required physical controls, including restricted access, alarm systems, surveillance, and secure storage. We prepare your security proposal and floor plan documentation as part of the application package.
The QPIC, SPIC, and all authorized alternates must hold valid security clearances from Health Canada. We advise on the clearance process, support the preparation of the required documentation, and coordinate the criminal record checks and supporting materials required for each designated individual.
For research institutions, clinical trial sponsors, and approved psychedelic-assisted therapy programs, we support the full Section 56 exemption application. This includes assessing your research protocol against CDSA requirements, coordinating with ethics boards, preparing the exemption application, and supporting Health Canada communication throughout the review. We also support Clinical Trial Applications (CTA) for studies involving scheduled psychedelic substances.
Once your licence or exemption is in place, your compliance obligations continue. Personnel changes, scope expansions, facility changes, and security clearance renewals all require formal notifications or amendments to Health Canada. Annual record-keeping and reporting requirements must be met consistently. We manage the full compliance lifecycle so your authorization remains current and your operations stay within the boundaries of your licence.
Pharmaceutical and Biotechnology Companies
Companies developing psilocybin, MDMA, or other psychedelic-derived drug products that require a Dealer’s Licence to support API production, research programs, or clinical development pipelines.
Research and Academic Institutions
Universities, research hospitals, and independent research organizations seeking Section 56 exemptions or Researcher Licences to conduct approved studies with scheduled psychedelic substances, including human clinical trials.
Psychedelic-Assisted Therapy Programs
Organizations developing Health Canada-authorized psilocybin-assisted or MDMA-assisted therapy programs, including Special Access Program (SAP) applications and approved clinical treatment settings.
Analytical Testing Laboratories
Labs seeking authorization to analyze psilocybin, psilocin, MDMA, or other scheduled substances for quality compliance, forensic purposes, or research support.
The latest on psychedelics licensing, Health Canada CDSA requirements, and regulatory developments in Canada.
Psilocybin and psilocin are Schedule III controlled substances under the CDSA, meaning activities involving them are prohibited unless specifically authorized by Health Canada. Authorized research, clinical trials, and therapeutic programs can proceed under a Dealer’s Licence or Section 56 exemption. Outside of those authorized pathways, possession, production, and distribution remain prohibited under federal law.
A Section 56 exemption under the CDSA allows Health Canada to exempt specific individuals or organizations from the prohibitions that would otherwise apply to controlled substances, for defined purposes. For psychedelics, exemptions have been granted for clinical researchers, healthcare practitioners working in approved therapeutic settings, and organizations conducting authorized clinical trials. Qualifying requires an approved protocol, ethics board approval, qualified personnel, and appropriate security arrangements. We assess whether your program qualifies and prepare the full exemption application.
Health Canada’s Office of Controlled Substances targets 270 calendar days from receipt of a complete application. That clock starts only after your application is accepted as complete. Incomplete applications, security documentation gaps, or QPIC credential issues generate additional information requests that add significant time before the review period even begins. A well-prepared, complete application at first submission is the most effective way to keep the process moving.
The QPIC must have the education, training, and experience required for the controlled substances and activities covered by the licence. Typically this includes a relevant post-secondary degree in science, pharmacy, or a related field, plus demonstrated experience working with controlled substances in a regulated environment. All QPIC candidates must pass a criminal record check and receive security clearance from Health Canada before the licence can be issued.
Yes, but the licence is tied to a physical facility located in Canada. You need a Canadian address, a compliant facility meeting Health Canada’s security requirements, and designated Canadian personnel including a QPIC and SPIC with valid security clearances. We work with international pharmaceutical and biotechnology companies setting up Canadian research or development operations and help them understand the full requirements before they invest in the setup.
Health Canada requires restricted access areas, alarm systems, surveillance cameras, secure storage for scheduled substances, visitor management procedures, and personnel security clearances. The specific level of security required depends on your site’s geographic location, the substances handled, and the quantities stored at any given time. We conduct a site assessment and prepare your security proposal as part of the application process.
Drug Establishment Licence (DEL)
For organizations that also require a DEL under the Food and Drug Regulations to authorize drug manufacturing or distribution activities.
DIN Application
For psychedelic-derived drug products that require a Drug Identification Number for authorized sale in Canada.
NDS and ANDS Registration
For organizations filing a New Drug Submission or Abbreviated New Drug Submission for a psychedelic-derived therapeutic product seeking market authorization.
OTC Drugs & Controlled Substances Hub
An overview of all QSS drug compliance services in Canada, including DIN applications, DEL registration, and NDS/ANDS submissions.
Whether you are applying for a Dealer’s Licence, seeking a Section 56 exemption, or working out which pathway applies to your research or clinical program, we can help you map out the right approach before you commit to an application.